Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma.
about
Resistance to Novel Antiandrogen Therapies in Metastatic Castration-Resistant Prostate CancerMolecular aspects of prostate cancer with neuroendocrine differentiationEmerging mechanisms of resistance to androgen receptor inhibitors in prostate cancerOrigins, genetic landscape, and emerging therapies of small cell lung cancerTransformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of originThe many faces of neuroendocrine differentiation in prostate cancer progressionDistinct genetic alterations in small cell carcinoma from different anatomic sitesTargeting the adaptive molecular landscape of castration-resistant prostate cancerNovel Insights into Molecular Indicators of Response and Resistance to Modern Androgen-Axis Therapies in Prostate CancerN-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate CancerCorrelation of PSMA-Targeted 18F-DCFPyL PET/CT Findings With Immunohistochemical and Genomic Data in a Patient With Metastatic Neuroendocrine Prostate Cancer.Aggressive variants of castration-resistant prostate cancerEMT and MET: necessary or permissive for metastasis?Molecular pathways and targets in prostate cancerA systems genetics approach identifies CXCL14, ITGAX, and LPCAT2 as novel aggressive prostate cancer susceptibility genes.Polycomb-mediated silencing in neuroendocrine prostate cancer.Frequent MED12 mutations in phyllodes tumours of the breast.Integrative molecular profiling of routine clinical prostate cancer specimens.Neuroendocrine Tumors of the Prostate: Emerging Insights from Molecular Data and Updates to the 2016 World Health Organization Classification.N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells.Comprehensive serial molecular profiling of an "N of 1" exceptional non-responder with metastatic prostate cancer progressing to small cell carcinoma on treatmentAndrogen Receptor-Dependent and -Independent Mechanisms Involved in Prostate Cancer Therapy Resistance.Flavokawain A induces deNEDDylation and Skp2 degradation leading to inhibition of tumorigenesis and cancer progression in the TRAMP transgenic mouse model.Translational and clinical implications of the genetic landscape of prostate cancer.Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer.GRK3 is a direct target of CREB activation and regulates neuroendocrine differentiation of prostate cancer cells.SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer.Circulating tumor cells capture disease evolution in advanced prostate cancer.Amplification of MUC1 in prostate cancer metastasis and CRPC developmentAndrogen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles.Genitourinary small cell malignancies: prostate and bladder.Targeting neuroendocrine prostate cancer: molecular and clinical perspectives.Multidisciplinary intervention of early, lethal metastatic prostate cancer: Report from the 2015 Coffey-Holden Prostate Cancer Academy Meeting.Epithelial-mesenchymal transition in prostatic disease.The selective PI3Kα inhibitor BYL719 as a novel therapeutic option for neuroendocrine tumors: Results from multiple cell line models.Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance.RB Loss Promotes Prostate Cancer Metastasis.Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer.Neuroendocrine Tumor of the Ureter: A Zebra Among Horses.Conversion of Prostate Adenocarcinoma to Small Cell Carcinoma-Like by Reprogramming.
P2860
Q26751237-71B7E10B-BA4D-4A13-A167-A5A87DCB3D0CQ26752910-AC93EB0C-7E92-4D90-8052-DC9B58E6F027Q26777310-3D661271-F76E-4085-A0BA-2B86BD7DFB61Q26798218-0E55D8E8-970B-484C-B2AA-68D8C409037FQ26826437-4D1C362F-9175-452A-9CE5-55E00A9E5315Q26992049-02671BCE-5008-4A55-ACA7-5A83EEDBA256Q27008242-27CED076-CFC7-4BA9-A7B1-3BA1CB8B96EBQ27022821-2DC12F4F-16F1-4230-839E-69E8EAD74977Q28067556-72F2D068-B69A-4891-B29C-6829F422BBD3Q28771715-9514ED72-AD99-4CE6-9EA2-9718107011C3Q31137270-E63B7F16-771F-4A6F-A941-109D05045BABQ33693256-9CB5678F-8593-4D93-8971-3E692B5FD1F5Q33869775-A4FF42C8-D0C7-4A80-B0A5-25330C760D68Q34365632-0456AA99-1119-44BA-B171-75A7AB880CDCQ34549577-3CAA6E8F-B223-490B-9868-B2F44405C0E2Q35336915-CF0F3B58-B561-4D75-ABCD-2E2E901E5231Q35603644-83DAC9F2-AB3B-4BDA-B479-1BA461EFEBD7Q35892022-2C0AF8AF-1FBC-45CB-8DC5-63D93BB2DBC4Q35925835-2B7C905E-DA6E-4AAD-A0C2-633B4AAB2BBFQ35980945-34DEA7DD-04C5-42D4-A7A3-4673D86BCC87Q36131601-26E52AA9-A41D-47C0-AFF6-570360E17DF5Q36398998-C36799F5-FC74-486E-A64C-D46C675C9B3BQ36561595-A4400EEE-3EEA-4433-B9D8-F3A57DBCA2F1Q37270512-D6E00C53-7026-4916-87B8-296509579E64Q37302524-3D54F9E5-D335-47CB-AB31-BF7895863E01Q37564369-E3FB5033-E706-48CA-99C4-2F97D19AEE5FQ37595372-900E6520-9DAE-4D1D-A676-9AF0498F8014Q37661448-AC655449-6CD0-48F5-BF16-FACD734A0FA0Q37696276-237687C0-0B25-4DD5-90DD-39C73ECE4CC0Q37709535-0D30FC00-33FE-4A31-8FA1-6111D4078A5FQ38352874-640D931D-79CB-4C79-82B1-E39B3B58DE73Q38362686-FC0DE61F-E4E9-4611-AA20-C0A3ADAA5345Q38610286-D1F63E0F-AEA8-41EB-A114-29E5E2D44A10Q38628753-7B8A80C3-AB91-498A-926C-8A4BABC26227Q38695102-96090D61-E8C8-42A6-A19F-574E41401087Q38722705-4FBC5CCF-55ED-45F0-B187-F2CAC0903A5CQ38727367-A516BE76-BAC0-4C1E-AA86-3E520E37186CQ38768101-F2DD6D86-EF9C-4215-B4C3-F10D5A85E0FEQ38792928-E0F5A59A-F7A9-42A8-B03C-B184B367EEB8Q38803108-ADB75AC8-6C8C-4C57-88FB-117D62DF250A
P2860
Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma.
@en
Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma.
@nl
type
label
Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma.
@en
Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma.
@nl
prefLabel
Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma.
@en
Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma.
@nl
P2093
P2860
P1476
Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma.
@en
P2093
Akshay Sood
Angelo M De Marzo
Christopher D Gocke
George J Netto
Hameed A Rahimi
Hsueh-Li Tan
Jessica Hicks
Jonathan I Epstein
Nilesh Gupta
Stacy Mosier
P2860
P304
P356
10.1158/1078-0432.CCR-13-1982
P407
P577
2013-12-09T00:00:00Z